Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Fecal microbiota transfer for steroid refractory acute GvHD

Mohamad Mohty • 7 Dec 2019
ASH 2019
General MaaT013
HERACLES

Steroid refractory graft-versus-host disease (GvHD) is associated with an absence of further therapeutic options, representing an unmet clinical need. Fecal microbiota transfer (FMT) proved to be a promising treatment modality in this challenging clinical situation. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the study of MaaT013, a standardized, pooled-donor, high-richness microbiota biotherapeutic, in patients with steroid-dependent or steroid-refractory intestinal acute GvHD. Results were quite impressive, MaaT013 provided a safe and successful treatment, supporting further exploration of this approach. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Mohamad Mohty

5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024
4:02
Moving CAR-T therapy into earlier lines of treatment for myeloma and the need for effective bridging
Mohamad Mohty • 15 Feb 2024

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals